Comparative Pharmacology
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus TECHNETIUM TC 99M PENTETATE KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus TECHNETIUM TC 99M PENTETATE KIT.
MPI INDIUM DTPA IN 111 vs TECHNETIUM TC-99M PENTETATE KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In-111 DTPA is a radiopharmaceutical that emits gamma radiation, used for imaging. DTPA chelates indium-111 and, after administration, distributes in the extracellular fluid and is cleared by glomerular filtration, allowing cisternography and renal imaging.
Technetium-99m pentetate is a radiopharmaceutical that, after intravenous administration, distributes in the extracellular space and is excreted by glomerular filtration. It is used to assess renal function and for imaging. The Tc-99m label emits gamma rays for detection.
Adult: 18.5 MBq (0.5 mCi) administered intravenously as a single dose for renal imaging.
Intravenous administration of 3-10 mCi (111-370 MBq) for renal imaging in adults. For cerebrospinal fluid (CSF) imaging, 0.5-2 mCi (18.5-74 MBq) intrathecally.
None Documented
None Documented
Terminal half-life: 2.5-4.0 hours (plasma); prolonged in renal impairment.
1.9 hours (terminal elimination half-life). Clinically, effective half-life is ~6 hours due to physical decay of Tc-99m (t½ 6.02 h) combined with biological clearance.
Renal: 90% within 24 hours via glomerular filtration; minimal biliary/fecal (<5%).
Primarily renal; 90-95% of injected dose excreted unchanged in urine within 24 hours via glomerular filtration. Minimal biliary/fecal elimination (<5%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical